Cargando…

Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies

BACKGROUND: The aim of this study was to assess the diagnostic performance of an autoantibody battery in patients receiving immune checkpoint inhibitors who experienced immune-related adverse events (irAEs). METHODS: We retrospectively analyzed several variables potentially related to irAEs, namely,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Les, Iñigo, Martínez, Mireia, Narro, Alicia, Pérez, Inés, Sánchez, Cristina, Puntí, Laura, Anaut, Pilar, Eguiluz, Saioa, Herrera, Alberto, Domínguez, Severina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172225/ https://www.ncbi.nlm.nih.gov/pubmed/34060971 http://dx.doi.org/10.1080/07853890.2021.1931956

Ejemplares similares

Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study
por: Les, Iñigo, et al.
Publicado: (2022)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
por: Les, Iñigo, et al.
Publicado: (2023)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
por: Zhou, Shi, et al.
Publicado: (2019)

Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events
por: Mathias, Kristen, et al.
Publicado: (2023)

Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer
por: Higashi, Tetsuo, et al.
Publicado: (2020)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
por: Gautron Moura, Bianca, et al.
Publicado: (2022)

Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan
por: Kanbayashi, Yuko, et al.
Publicado: (2023)

Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events
por: Imafuku, Keisuke, et al.
Publicado: (2017)

Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series
por: Ganta, Nagapratap, et al.
Publicado: (2022)

Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis
por: Zhao, Xin, et al.
Publicado: (2022)

Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab
por: Hara, Yoshihiro, et al.
Publicado: (2022)

Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab
por: Yamauchi, Ichiro, et al.
Publicado: (2019)

Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
por: Dudzińska, Marta, et al.
Publicado: (2020)

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
por: Masuda, Ken, et al.
Publicado: (2019)

SUN-414 Immune Related Adverse Events: Isolated ACTH Deficiency with Nivolumab/Ipilimumab Combination Therapy
por: Magdaleno, Angela, et al.
Publicado: (2019)

Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab
por: Mizutani, Kosuke, et al.
Publicado: (2021)

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
por: Yoneda, Hiroto, et al.
Publicado: (2021)

Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab
por: Sawada, Ryo, et al.
Publicado: (2021)

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2018)

Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook
por: Möhn, Nora, et al.
Publicado: (2019)

A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
por: Sekai, Ikue, et al.
Publicado: (2021)

Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events
por: Müller-Jensen, Leonie, et al.
Publicado: (2023)

Adverse clinical events caused by pacemaker battery depletion: two case reports
por: Liu, Junpeng, et al.
Publicado: (2020)

Umbilical lichen planus induced by nivolumab()
por: Martos-Cabrera, Luisa, et al.
Publicado: (2023)

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
por: Bins, Sander, et al.
Publicado: (2018)

Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma
por: Billon, Emilien, et al.
Publicado: (2019)

Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report
por: Sakoh, Takashi, et al.
Publicado: (2019)

A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy
por: Hirasawa, Yuya, et al.
Publicado: (2021)

Steven-Johnson Syndrome: A Rare but Serious Adverse Event of Nivolumab Use in a Patient With Metastatic Gastric Adenocarcinoma
por: Saad, Eltaib, et al.
Publicado: (2022)

Rheumatoid Arthritis Symptoms Diagnosed by Rheumatic Immune-related Adverse Events Caused by Nivolumab in a Patient with Esophageal Cancer
por: Yasui, Sho, et al.
Publicado: (2022)

Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition
por: Ghosh, Nilasha, et al.
Publicado: (2022)

Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment‐Related Adverse Events From the CheckMate 040 Study
por: Julien, Karen, et al.
Publicado: (2020)

Two cases of delayed onset of immune‐related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer
por: Nakai, Yasutomo, et al.
Publicado: (2021)

The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma
por: Yazaki, Tomotaka, et al.
Publicado: (2021)

Severe eosinophilia and subsequent dermatologic immune‐related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab
por: Matsumoto, Takeshi, et al.
Publicado: (2022)

Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism
por: Kobayashi, Mizuki, et al.
Publicado: (2022)

Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer
por: Takada, Shinya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g2oebau50j8vk547osdo6l8mno